Comments
Here are answers to readers’ queries on the performance of their stock holdings.
What is the medium and long-term technical outlook for the stock of GSK Pharma.
Panini Deshpande, Ashok Bedi
GlaxoSmithKline Pharmaceuticals (₹3,314.2): The stock of GlaxoSmithKline Pharmaceuticals has been on a long-term uptrend since taking support at ₹800 in early 2008. This will continue as long as the stock trades above the significant support band between ₹1,850 and ₹2,000. Investors with a long-term horizon can hold the stock with a stop-loss at ₹1,850 levels. The intermediate-term trend is also up for the stock.
However, after registering a new high at ₹3,550 in late January this year, the stock has been on a sideways consolidation move between ₹3,050 and ₹3,500.
The medium- to intermediate-term uptrend will remain in place as long as the stock trades above the significant support level of ₹2,900. Investors with a medium-term perspective can consider holding their long positions with a stop-loss at this level. Only an emphatic fall below this level will mar the uptrend and pull the stock down to ₹2,650 and then to ₹2,400 levels in the medium term.
A fall below the immediate short-term key support of ₹3,240 can pull the stock down to the lower boundary of the sideways range at ₹3,050 levels. On the upside, a conclusive breakthrough of ₹3,500 can take the stock higher to ₹3,800 levels in the long term.
I bought Karnataka Bank at ₹155. Please advise on the outlook for the stock.
Rajiv Shaw
Karnataka Bank (₹128.3): You have purchased the stock at around the key resistance level of ₹157. The stock tested this resistance in early December 2014 and then reversed downwards in late January.
Since then, the stock has been on a short-term downtrend. However, it found support at a significant base at ₹118 recently and bounced back.
But, failure to rally above ₹135 can pull the stock down once again to ₹118 levels. Further fall below this level can pull the stock down to ₹110 levels. You can make use of these support levels to average with a stop-loss at ₹106.
A strong breakthrough of the significant resistance at ₹135 can take the stock higher to ₹150 and ₹157 levels in the medium term. The stock needs to decisively break ₹157 for an up move to ₹180 in the long term.
I have bought Arvind Remedies at ₹24. But the stock price has fallen since then. Please advise if I should hold or sell it?
KV Rajendran Nair
Arvind Remedies (₹21.19): After marking a multi-year high at ₹66 in September 2014, the stock reversed direction and fell non-stop until it found support at ₹10 in late March 2015.
However, it did a volte-face and rallied sharply breaking key resistances at ₹15 and ₹20. The stock’s ongoing rally is backed with good daily volumes. It has almost bounced back to your purchase price. As the stock faces a key resistance at ₹25, there could be minor corrective declines. You can make use of the these dips to average and then book profits as early as possible.
Strong rally beyond ₹25 can push the stock northwards to ₹30 in the short- to medium-term. But the stock needs to decisively breach its significant long-term resistance level of ₹30 for a further rally to ₹35 or ₹38 levels in the long run.
On the downside, a decisive plunge below the support level of ₹15 can pull the stock down to ₹10 in the medium term. Next key supports are pegged at ₹8 and ₹6.5 levels.
What is the outlook for Alkyl Amines Chemicals?
P. Ravi
Alkyl Amines Chemicals (₹335.3): After a corrective fall, the stock moved towards the 38.2 per cent fibonacci retracement level of the prior uptrend and found support at ₹280 in late March 2015.
The stock then bounced back smartly. It now tests a key hurdle at ₹350 levels. A decisive breakout of this level is needed to strengthen the long-term uptrend and take the stock higher to the ₹400-410 band in the coming months.
Inability to breach this resistance can pull the stock down to ₹320 or ₹300 levels. Next key supports are at ₹280 and ₹240. The long-term uptrend will remain in place as long as the stock hovers above ₹240 levels.
Send your queries to techtrail@thehindu.co.in
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.